As the world’s second-largest healthcare market, China spends about $575 billion a year on the sector, roughly equivalent to Sweden’s GDP. But because of China’s large population, that translates into only $420 in per capita healthcare spending, just 4% of what an average American spends. This healthcare supply shortage is exacerbated by rising demand from wealthier Chinese who seek quality care, better insurance, and diverse services.
On the regulatory side, the Chinese government continues to reform the healthcare sector by allowing doctors to work
outside the public hospital system, encouraging the privatization of hospitals, and expanding public healthcare insurance to cover private hospitals.
The significant mismatch between supply and demand, coupled with policy changes to support the sector, have incentivized private investment to flock into areas ranging from advanced pharmaceuticals and medical devices to primary care clinics, elderly care, and insurance products.
Jiangsu Hengrui Medicine develops, manufactures, and supplies pharmaceuticals, including anti-cancer and cardiovascular drugs and surgical anesthesia. One of its anesthesia products has gained FDA approval for the US market. The company has also set up research and testing facilities in the United States.
Hengrui USA LLC 2005 Eastpark Blvd Cranbury, NJ 08512 Ph: 609.619.3156
The company has a subsidiary in New Jersey, which, by the end of 2016, had added a clinical center and an R&D center for about $1.2 million.
In November 2014, the company established its European subsidiary in Willich, Germany with registered capital of $1 million.